Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $210M | $69.6M | $70.8M | $81.4M |
| Revenue growth | — | -66.9% | 1.8% | 14.9% |
| Operating income | -$123M | -$166M | -$131M | -$121M |
| Operating margin | -58.8% | -238.6% | -184.4% | -149.3% |
| Net income | -$157M | -$240M | -$158M | -$143M |
| Net margin | -74.9% | -345.1% | -222.8% | -175.3% |
| EPS (diluted) | -$2.01 | -$2.94 | -$1.62 | -$1.12 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating cash flow | -$138M | -$119M | -$124M | -$141M |
| Capital expenditures | $687K | $3.22M | $867K | $264K |
| Free cash flow | -$139M | -$122M | -$125M | -$141M |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & equivalents | $326M | $279M | $251M | $261M |
| Total assets | $491M | $355M | $322M | $323M |
| Total liabilities | $411M | $503M | $525M | $509M |
| Shareholders' equity | $79.5M | -$148M | -$203M | -$186M |
| Retained earnings | -$1.10B | -$1.34B | -$1.49B | -$1.64B |
| Shares (wtd avg diluted) | 78.2M | 81.7M | 97.2M | 127M |
Every figure is extracted from ADC Therapeutics SA’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.